- Home
- APVO vs MBIO Comparison
APVO vs MBIO Comparison
Compare APVO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- MBIO
- Stock Information
- Founded
- APVO 2016
- MBIO 2015
- Country
- APVO United States
- MBIO United States
- Employees
- APVO N/A
- MBIO 80
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- MBIO Health Care
- Exchange
- APVO Nasdaq
- MBIO Nasdaq
- Market Cap
- APVO 6.5M
- MBIO 7.3M
- IPO Year
- APVO N/A
- MBIO N/A
- Fundamental
- Price
- APVO $4.46
- MBIO $5.55
- Analyst Decision
- APVO Strong Buy
- MBIO Strong Buy
- Analyst Count
- APVO 1
- MBIO 1
- Target Price
- APVO $296.00
- MBIO $2.00
- AVG Volume (30 Days)
- APVO 90.6K
- MBIO 468.6K
- Earning Date
- APVO 03-04-2025
- MBIO 03-10-2025
- Dividend Yield
- APVO N/A
- MBIO N/A
- EPS Growth
- APVO N/A
- MBIO N/A
- EPS
- APVO N/A
- MBIO N/A
- Revenue
- APVO N/A
- MBIO N/A
- Revenue This Year
- APVO N/A
- MBIO N/A
- Revenue Next Year
- APVO N/A
- MBIO N/A
- P/E Ratio
- APVO N/A
- MBIO N/A
- Revenue Growth
- APVO N/A
- MBIO N/A
- 52 Week Low
- APVO $3.65
- MBIO $5.19
- 52 Week High
- APVO $399.60
- MBIO $76.00
- Technical
- Relative Strength Index (RSI)
- APVO 38.21
- MBIO 31.43
- Support Level
- APVO $4.32
- MBIO $5.19
- Resistance Level
- APVO $4.79
- MBIO $13.30
- Average True Range (ATR)
- APVO 0.45
- MBIO 2.31
- MACD
- APVO 0.15
- MBIO -0.47
- Stochastic Oscillator
- APVO 19.53
- MBIO 2.14
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.